The cost of Wegovy can exceed $1,000 each month, but starting July 1, 2026, a limited group of Medicare beneficiaries may access it for just $50 monthly. However, the list of qualifiers is more restrictive than it appears, and some may be surprised by exclusions if they assume they’re eligible.
The Centers for Medicare & Medicaid Services has introduced a program called the Medicare GLP-1 Bridge. This is a temporary initiative, available across the country, running parallel to but separate from Part D until December 31, 2027. Enrollment in Part D is needed, but the drug isn’t required to be on your plan’s formulary, and the plan doesn’t have to opt in. If your BMI, health history, and prescription align, the copay stays at $50 monthly for a covered GLP-1. But if any of those factors are misaligned, the bridge won’t apply.
Who Actually Qualifies
There are three drugs covered: Wegovy (available as an injection or tablet), Zepbound (only the KwikPen, no vials or single-dose pens), and Foundayo (tablet). To qualify, you need to be at least 18 and enrolled in a Medicare drug plan that qualifies. These include standalone PDPs, most HMO and PPO MA-PD plans, Special Needs Plans, and some employer or union group waiver plans. Certain private fee-for-service, cost, and PACE plans are excluded unless you also have an eligible standalone PDP. If you’re on Original Medicare without Part D, you’ll have to enroll to access the bridge.
Eligibility also depends on BMI and comorbidities, with strict criteria set by CMS. Generally, the measurements and diagnoses need to have been recorded at the start of GLP-1 therapy:
- BMI of 35 or higher: qualifies based solely on BMI.
- BMI of 30 or higher plus one of: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease at stage 3a or higher. CMS defines uncontrolled hypertension as having blood pressure over 140 systolic or 90 diastolic despite using two blood-pressure meds.
- BMI of 27 or higher plus one of: prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
A doctor needs to certify the diagnosis and submit prior authorization. The prescription must be specifically for weight reduction or maintenance while following a nutrition and exercise plan. Just saying you have a high BMI or a vague blood pressure issue won’t be enough.
The Exclusions That Trip People Up
This is the section that confuses many. The bridge doesn’t apply if you’ve received a GLP-1 through Part D in 2026 or are being prescribed one for an indication that’s already eligible for Part D coverage, even if it’s not on your plan’s formulary. Specifically, people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or certain liver conditions are excluded. That’s narrower than simply having “fatty liver disease.”
For these individuals, they must revert to their Part D plans, where cost-sharing varies based on the drug’s tier, deductible, and formulary. Costs can exceed $50, and obtaining the drug may require a formulary exception.
It’s important to consider the context. For instance, a 68-year-old with type 2 diabetes and a BMI of 34 can access a GLP-1 through Part D but isn’t eligible for the $50 copay. On the other hand, a 68-year-old with prediabetes and a BMI of 28 may qualify if the prescription is for weight management.
A prior heart attack adds complexity. It can satisfy the Bridge’s BMI-27 requirement, but if Wegovy is given to lower cardiovascular risk, that’s a Part D claim. The diagnosis may be the same, but the prescription’s objective switches the track.
How the $50 Copay Interacts With the Rest of Your Medicare Bill
The bridge operates outside Part D, meaning the $50 copay doesn’t count toward your Part D deductible or the annual out-of-pocket cap. You’ll still pay your standard Part D premium and any IRMAA surcharges. In 2026, these surcharges range from $14.50 to $91.00 each month, depending on your tier. The bridge doesn’t alter this situation.
Extra Help won’t lessen the $50 copay, and payments can’t be divided through the Medicare Prescription Payment Plan. It also doesn’t bring you closer to Part D’s $2,100 annual out-of-pocket limit. The Bridge offers a cheaper alternative, yet keeps its own separate record.
For retirees witnessing only a slight 2.8% increase in their Social Security checks in 2026, a $50 monthly cost is significant. Twelve months of fills at $600 is quite a difference when the drug’s annual price can reach into five figures. That’s genuine assistance, given everything falls into place.
What to Do
The Bridge has a low copay but a narrow eligibility door. Here are three steps to determine if it’s worth pursuing.
- Verify your Part D enrollment and plan type. Both are needed to access the bridge. If you’re on Original Medicare without drug coverage, you have to add one first. The next enrollment period is from October 15 to December 7, with most new coverage starting January 1.
- Request your primary care doctor or cardiologist to compile your BMI at the start of therapy, qualifying diagnoses, and current treatment details on one page, checking against the eligibility tiers prior to asking for a prescription. If your authorization gets denied due to inaccuracies, the doctor can resubmit it with the correct info. The Bridge lacks a formal appeal process.
- If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying liver conditions, skip the bridge and inquire with your Part D plan about which GLP-1s are included, their tier, and how to seek an exception if needed. That’s your real coverage route.
This isn’t broad coverage for weight-loss meds under Medicare. It’s a narrow opportunity, but for those who fit the criteria, finding $50 could be worthwhile.
Program rules reflect the 2026 plan year and the Medicare GLP-1 Bridge as detailed by CMS and Medicare.gov.
